Please login to the form below
Sprycel
This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.
BMS’ Opdivo stalls in Q3, but overall figures still top expectations
and leukaemia drug Sprycel (dasatinib) which brought in $558m, also up 14%.
Latest news
-
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
-
NICE backs BMS leukaemia drug Sprycel
Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment of adults with CML. ... BMS has now agreed a patient access scheme for Sprycel, which brought in sales of $472m this
-
Opdivo drives gain in BMS sales, but business revamp coming
BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
-
England's Cancer Drugs Fund: Fixing a broken system
Bristol-Myers Squibb's Sprycel (dasatinib):. for treatment of lymphoid blast crisis chronic myeloid leukamia.
-
Pharma condemns Cancer Drugs Fund cuts
Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
More from news
Approximately 4 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Interview: Harvey Berger and Timothy Clackson, Ariad
recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... The drug was then developed with the specific intention of
-
Intellectual property threats in the BRIC markets
of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
